Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) FCF Margin (2023 - 2025)

CG Oncology (CGON) has disclosed FCF Margin for 3 consecutive years, with 1559.3% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 301767.0% year-over-year to 1559.3%, compared with a TTM value of 3278.07% through Dec 2025, up 365319.0%, and an annual FY2025 reading of 3278.07%, up 365319.0% over the prior year.
  • FCF Margin was 1559.3% for Q4 2025 at CG Oncology, up from 2338.6% in the prior quarter.
  • Across five years, FCF Margin topped out at 1559.3% in Q4 2025 and bottomed at 1464500.0% in Q4 2023.
  • Average FCF Margin over 3 years is 172614.17%, with a median of 9727.3% recorded in 2024.
  • The sharpest move saw FCF Margin soared 145992303bps in 2024, then tumbled -5141322bps in 2025.
  • Year by year, FCF Margin stood at 1464500.0% in 2023, then soared by 100bps to 4576.97% in 2024, then surged by 66bps to 1559.3% in 2025.
  • Business Quant data shows FCF Margin for CGON at 1559.3% in Q4 2025, 2338.6% in Q3 2025, and 56332.69% in Q1 2025.